The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP
Body mass index (BMI) ≥ 28.0 kg/m2;
The results of PSG meet the diagnosis criteria of OSA and with an AHI≥15 at screening;
Have been on PAP therapy for at least 3 consecutive months prior to screening and plan to continue PAP therapy during the study;
Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
History of endocrine disorders which have significant impact on body weight;
Diagnosis of diabetes (except gestational diabetes), ketoacidosis or hypertonic state/coma;
HbA1c ≥6.5% at screening;
Fasting blood glucose ≥7.0 mmol/L or 2-hour blood glucose ≥11.1 mmol/L after oral glucose tolerance test (OGTT) at screening; participants with FBG ≥6.1 mmol/L but <7.0 mmol/L require OGTT;